Drug Approval | February 26, 2024
Piramal Pharma gets Form 483 with 2 observations from USFDA for Lexington, USA facility
The observations do not pose any risk to site's compliance standards or its business continuity
The observations do not pose any risk to site's compliance standards or its business continuity
_Rupak_Singla_256_384.jpg)
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
The restructuring aims to create synergies across the business and strengthen capital structure
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
